ArticleJournal of enzyme inhibition and medicinal chemistry2021
Development of novel isatin-nicotinohydrazide hybrids with potent activity against susceptible/resistant
Article in Journal of enzyme inhibition and medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Evaluation of Novel Isatin-Schiff Base Derivatives: Monoamine Oxidase Inhibition and Antimicrobial Assessment.ChemMedChem · 2026Article
- Discovery of novel anti-RSC advances · 2026Article
- Synthesis and Biological Evaluation of Imidazopyridine-Isatin Hybrids as Inhibitors ofDrug design, development and therapy · 2026Article
- Synthesis, DFT study, in silico ADMET evaluation, molecular docking, and QSAR analysis of new anti-tuberculosis drugs derived from 2-hydroxybenzohydrazide derivatives.Molecular diversity · 2025Article
- Isoniazid-rhodanine molecular hybrids: design, synthesis, antimycobacterial activity and computational validation.RSC advances · 2025Article
- A survey of isatin hybrids and their biological properties.Molecular diversity · 2025Review
- Article
- Identification of sulphonamide-tetheredJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Discovery of pyrimidine-tethered benzothiazole derivatives as novel anti-tubercular agents towards multi- and extensively drug resistantJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Development of Novel Isatin-Tethered Quinolines as Anti-Tubercular Agents against Multi and Extensively Drug-ResistantMolecules (Basel, Switzerland) · 2022Article
- Development of novel isatin thiazolyl-pyrazoline hybrids as promising antimicrobials in MDR pathogens.RSC advances · 2022Article
- A review of the global climate change impacts, adaptation, and sustainable mitigation measures.Environmental science and pollution research international · 2022Review
- A Mini Review on Isatin, an Anticancer Scaffold with Potential Activities against Neglected Tropical Diseases (NTDs).Pharmaceuticals (Basel, Switzerland) · 2022Review
- GC/MS Profiling, Anti-Collagenase, Anti-Elastase, Anti-Tyrosinase and Anti-Hyaluronidase Activities of aPlants (Basel, Switzerland) · 2022Article
- Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Structural homology between 11 beta-hydroxysteroid dehydrogenase andFrontiers in endocrinology · 2022Article
- Development of novel benzofuran-isatin conjugates as potential antiproliferative agents with apoptosis inducing mechanism in Colon cancer.Journal of enzyme inhibition and medicinal chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Joining the global fight against Tuberculosis, the world's most deadly infectious disease, herein we present the design and synthesis of novel isatin-nicotinohydrazide hybrids (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.